Analyse court terme - NOVARTIS : Les prix dépassent la moyenne mobile, c'est un signal de force.
La tendance est momentanément interrompue par une correction. Elle approche du support à 74,30 CHF, qui est également le niveau d'invalidation. Ceci pourrait relancer le mouvement haussier. Le prochain objectif est à 82,00 CHF. Le niveau d'invalidation est sous 74,20 CHF.Arguments :
- La résistance a été dépassée, mais elle est réintégrée. Les prix peuvent baisser.
- Le retracement de 50% est atteint, il cause le repli.
- Les prix dépassent la moyenne mobile, c'est un signal de force.
Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.
DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.